[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","waqg9kb55vd6l3vkyzmnli69n","revision",2,"title","DR. REDDY’S LABORATORIES LIMITED 提交 6-K 文件","originalTitle","6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)","summary","DR. REDDY’S LABORATORIES LIMITED 提交 6-K 文件，披露公司信息。文件包含公司注册信息及联系方式。公司为印度制药企业，注册地址位于海得拉巴。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-23T18:02:56.000Z","discoveredAt","2026-10-23T18:18:30.298Z","timelineAt","category","tip","tags",[80,81,82],"stockSymbols",[79],"score",15,"selected",false,"channel","news","story",{"_71":72,"_15":73},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":69},"hasTranslation","bodyLanguage","original","factId","fwznwJAcFh3o",{"_71":72,"_15":73},"reportCount","additionalSourceCount",0,"developmentCount","publicId","e88de77f-5768-4d3a-ad22-70cd809ecc12","Dr. Reddy's Laboratories 提交6-K文件",{"_71":72,"_15":73},"zh","

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO\nRULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2026

Commission\nFile Number 1-15182

DR.\nREDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

\n\n \n \n \n \n \n

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K\nin paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission\nin paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K\nin paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7)\nonly permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private\nissuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized\n(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities\nare traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the\nregistrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other\nCommission filing on EDGAR.

Indicate by check mark whether by furnishing\nthe information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)\nunder the Securities Exchange Act of 1934.

\n\n \n \n \n \n \n

Yes ☐

No ☒

If “Yes” is marked, indicate below the file number assigned\nto registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

\n \n \n \n \n \n \n \n \n \n \n \n

Exhibit \n Number		Description\n of Exhibits

99.1		Intimation\n dated October 23, 2026

SIGNATURES

Pursuant to the requirements of the\nSecurities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	DR. REDDY’S LABORATORIES LIMITED \n\n (Registrant) \n\n

Date: October 23, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

","zhKind","complete","RDY","政策与监管","退市","其他","aihot","/items/waqg9kb55vd6l3vkyzmnli69n","https://www.sec.gov/Archives/edgar/data/1135951/000157587226000721/0001575872-26-000721-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792972800&sig=9d173b888aad17ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792972800&sig=997f44534d647b46 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792972800&sig=923979fb4a1845f5 96w","changelogVersion","2026-10-01T08:00"]